drug
Lumizyme
Marketedupdated 5mo agoby Genzyme Corp
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Lumizyme
- phase3Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
- phase4China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
- —A Global Prospective Observational Registry of Patients With Pompe Disease
- phase2A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
- —Avalglucosidase Alfa Pregnancy Study
- phase4Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
- phase3A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
- —A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
News(1)
- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseSanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking to…endpoints · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that